SCHEMBL10185017

SCHEMBL10185017

CN(C)c1cc(C(F)(F)F)ccc1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
CFTR P13569 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.40
RAB9A P51151 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
MAPT P10636 3/20 0.39
GAA P10253 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
GFER P55789 1/20 0.39
NOS3 P29474 1/20 0.38
NOS2 P35228 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2968966 0.84 GAA (0.50) ALDH1A1KDM4EPKMHPGDHSD17B10
SCHEMBL20073799 0.79 KIF11 (0.43) ALDH1A1KDM4EPKMHPGDHSD17B10
SCHEMBL29686357 0.79 KIF11 (0.43) ALDH1A1KDM4EPKMHPGDHSD17B10
SCHEMBL13696457 0.78 KDM1A (0.40) MAPTGAAKIF11IDH2
SCHEMBL9234432 0.78 PDE2A (0.42) L3MBTL1GAAKIF11IDH2
SCHEMBL18160746 0.78 IDH2 (0.38) GAAKMT2AMEN1KIF11IDH2
SCHEMBL2975541 0.77 CYP2D6 (0.42) ALDH1A1KDM4EPKMHPGDHSD17B10
SCHEMBL28582842 0.76 IDH2 (0.37) ALDH1A1KDM4EHPGDHSD17B10RAB9A
SCHEMBL27766668 0.76 MAPT (0.47) ALDH1A1KDM4ETSHRL3MBTL1SLC6A4
SCHEMBL3978228 0.76 IDH2 (0.37) RAB9ASLC6A2SLC6A4SLC6A3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023016518-A1 HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF 四川海思科制药有限公司 2023-02-16 WO disclosed
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2012-02-16 US disclosed
WO-2010078408-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040951-A1 HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF ALDH1A1 1934/4885KDM4E 2722/4885PKM 1926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.